Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: 20-Sep-2022 09:17:55

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Specialists Trusts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Ambulance Trusts
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • Acute Trusts
  • NHS Trusts (England) - Chief Executive

Action category: Action

Title: Tecovirimat as a treatment for patients hospitalised due to Monkeypox viral infection

Broadcast content: Tecovirimat is now available to symptomatic patients hospitalised due to a severe or complicated monkeypox infection in line with the published UK interim clinical policy statement. Supply is being managed via specialist regional adult infectious diseases centres.  Clinicians are actively encouraged to support recruitment of patients with laboratory confirmed monkeypox infection and with active skin or mucosal lesions, but who do not require hospital admission, to the PLATINUM trial.  An observational study, MOSAIC, is exploring outcomes of patients with monkeypox infection across Europe.

Additional information: This alert does not need to be cascaded to primary care

Alert reference: CEM/CMO/2022/012


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency